	US 12,109,194 B2
	Synergistic combination therapy for treating ALS
Peter Milner, Los Altos, CA (US); Nadia Litterman, Los Altos, CA (US); and Mark Midei, Los Altos, CA (US)
Assigned to BioJiva LLC, San Jose, CA (US)
Filed by BioJiva LLC, San Jose, CA (US)
Filed on Mar. 1, 2022, as Appl. No. 17/684,279.
Application 17/684,279 is a continuation in part of application No. PCT/US2022/015366, filed on Feb. 4, 2022.
Application 17/684,279 is a continuation in part of application No. 17/169,271, filed on Feb. 5, 2021, granted, now 11,351,143.
Claims priority of provisional application 63/310,544, filed on Feb. 15, 2022.
Claims priority of provisional application 63/310,541, filed on Feb. 15, 2022.
Prior Publication US 2022/0249442 A1, Aug. 11, 2022
Int. Cl. A61K 31/4152 (2006.01); A61K 31/202 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/4152 (2013.01) [A61K 31/202 (2013.01); A61P 25/28 (2018.01)]

18 Claims

1. A method for reducing the rate of disease progression of ALS in a patient the method comprising administering to the patient a therapeutically effective amount of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a deuterated arachidonic acid or a prodrug thereof; wherein the rate of disease progression in the patient is less than the aggregate achieved by either drug; and wherein the deuterated arachidonic acid or a prodrug thereof is administered using a dosing regimen that includes a loading dose and a maintenance dose.